Soligenix

Soligenix Accounts Payable

The Accounts Payable of Soligenix (SNGX) as of Oct 19, 2026 is 1.12 M USD. In the previous year, Accounts Payable was 667,896.00 USD — a change of 67.02% (higher).

Accounts Payable

1.12 MUSD

YoY

67.02%

Last updated:

Accounts Payable of Soligenix is 2025 1.12 M USD. Accounts Payable of Soligenix was 2024 667,896.00 USD. It decreases by 67.02% higher compared to the previous year.

The Soligenix Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
2.13 M USD
Jan 1, 2019
2.74 M USD
Jan 1, 2020
2.13 M USD
Jan 1, 2021
2.93 M USD
Jan 1, 2022
3.87 M USD
Jan 1, 2023
1.11 M USD
Jan 1, 2024
667,896.00 USD
Jan 1, 2025
1.12 M USD
The Soligenix Accounts Payable history
YEARAccounts PayableYoY
1.12 MUSD+67.02%
667,896.00USD-39.90%
1.11 MUSD-71.25%
3.87 MUSD+32.14%
2.93 MUSD+37.36%
2.13 MUSD-22.14%
2.74 MUSD+28.65%
2.13 MUSD+21.25%
1.75 MUSD+2.67%
1.71 MUSD-40.47%
2.87 MUSD-4.47%
3.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Accounts Payable of Soligenix is 1.12 M USD in 2025.

Accounts Payable of Soligenix changed from 667,896.00 USD to 1.12 M USD, representing a 67.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Soligenix since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Soligenix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Soligenix

All Key Metrics — Soligenix